Natera, Sequenom, Thermo Fisher, Roche diagnostic news

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to review the case and the patent eligibility criteria established in the court’s 2012 decision in Mayo Collaborative

Read the full 529 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE